Literature DB >> 25131537

Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.

Riccardo Rondanin1, Daniele Simoni2, Romeo Romagnoli2, Riccardo Baruchello2, Paolo Marchetti2, Cristiana Costantini2, Sara Fochi2, Giacomo Padroni2, Stefania Grimaudo3, Rosaria Maria Pipitone3, Maria Meli4, Manlio Tolomeo5.   

Abstract

STATs are transcription factors acting as intracellular signaling after stimulation with cytokines, growth factors and hormones. STAT5 is also constitutively active in many forms of cancers, including chronic myelogenous leukemia, acute lymphoblastic leukemia and Hodgkin's lymphoma. Recently, literature reported that the neuroleptic drug pimozide inhibits STAT5 phosphorylation inducing apoptosis in CML cells. We undertook an investigation from pimozide structure, obtaining simple derivatives with cytotoxic and STAT5-inhibitory activity, two of them markedly more potent than pimozide.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; BCR/ABL expressing leukemia; Cell growth inhibition; Pimozide; STAT5 inhibitors

Mesh:

Substances:

Year:  2014        PMID: 25131537     DOI: 10.1016/j.bmcl.2014.07.069

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Carlota Lopez-Cara; Riccardo Rondanin; Daniele Simoni; Ernest Hamel; Stefania Grimaudo; Rosaria Maria Pipitone; Maria Meli; Manlio Tolomeo
Journal:  Eur J Med Chem       Date:  2015-11-27       Impact factor: 6.514

2.  Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis.

Authors:  Shunmoogum A Patten; Dina Aggad; Jose Martinez; Elsa Tremblay; Janet Petrillo; Gary Ab Armstrong; Alexandre La Fontaine; Claudia Maios; Meijiang Liao; Sorana Ciura; Xiao-Yan Wen; Victor Rafuse; Justin Ichida; Lorne Zinman; Jean-Pierre Julien; Edor Kabashi; Richard Robitaille; Lawrence Korngut; J Alexander Parker; Pierre Drapeau
Journal:  JCI Insight       Date:  2017-11-16

3.  MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia.

Authors:  Quan Li; Yaohui Wu; Jian Zhang; Tienan Yi; Weiming Li
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 4.  Mechanism of Human Telomerase Reverse Transcriptase (hTERT) Regulation and Clinical Impacts in Leukemia.

Authors:  Mot Yee Yik; Adam Azlan; Yaashini Rajasegaran; Aliaa Rosli; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

5.  Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.

Authors:  X Zhu; H Zhao; Z Lin; G Zhang
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

6.  FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.

Authors:  Ayako Nogami; Gaku Oshikawa; Keigo Okada; Shusaku Fukutake; Yoshihiro Umezawa; Toshikage Nagao; Tetsuya Kurosu; Osamu Miura
Journal:  Oncotarget       Date:  2015-04-20

7.  Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.

Authors:  Qianyin Li; Zhenglan Huang; Miao Gao; Weixi Cao; Qin Xiao; Hongwei Luo; Wenli Feng
Journal:  Int J Mol Sci       Date:  2017-03-02       Impact factor: 5.923

8.  The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma.

Authors:  Jia-Jie Chen; Nan Cai; Guan-Zhong Chen; Chang-Chang Jia; Dong-Bo Qiu; Cong Du; Wei Liu; Yang Yang; Zi-Jie Long; Qi Zhang
Journal:  Oncotarget       Date:  2017-03-14

9.  Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis.

Authors:  Silvia Pozzi; Sai Sampath Thammisetty; Jean-Pierre Julien
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

10.  MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia.

Authors:  Zhu Xishan; Lin Ziying; Du Jing; Liu Gang
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.